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In defence of the case for the derivation of mesenchymal stem 
cells from human embryonic stem cells. 
S. Pringle, S. Minger, United Kingdom 
The current era in biological science has been dubbed the dawning 
of the age of regenerative medicine, and in particular, the turn of 
the stem cell. As our understanding of developmental pathways 
blossoms, so does the array of possible therapeutic ends to our 
endeavours. This extended abstract aims to outline the case for the 
derivation of mesenchymal stem cells (MSCs) from human embryonic 
stem cells (hESCs). 
Mesenchymal stem cells (MSCs) are isolated relatively easily 
from an increasingly diverse array of sites within the mammalian 
donor, albeit with some degree of heterogeny and a reliance on 
the enhanced adherence of MSCs to plastic, in comparison with 
other cell lineages 1-12. Multipotency of these MSCs has been 
demonstrated time and again ex vivo 13-15. Indeed, it seems that 
MSCs are not, as initially postulated, restricted to differentiating into 
the chondrocytic, osteocytic and adipocytic mesodermal cell types. 
The emergence of endothelial, neuronal and blood-cell like cultures 
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Although there are still some problems with maintaining the in vivo 
stability of cell types derived from MSCs and the accurate simulation 
of the joint micro-environment in vitro, there can be no doubt that 
progress is being made. If optimising the use of MSCs derived from 
somatic sources for regenerative purposes is simply a matter of 
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from human embryonic stem cells (hESCs) be likened to jumping on 
band wagon for the band wagon’s sake? Human embryonic stem 
cells (hESCs) have enjoyed a celebrity status of late, underpinned 
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Reports of the derivation of somatic stem cell-like cells from hESCs 
are becoming more numerous 8,37-40, including derivation of 
MSCs 41,42. Chondrogenesis, osteogenesis and adipogenesis have 
been demonstrated with relative ease from the hESC-derived MSC 
populations41,42, and appear to be comparable to somatic tissue-
derived MSCs in their differentiation capabilities. They also however 
have four potential advantages compared to the isolation of MSCs 
from tissues within the patient. Firstly, standardised in vitro derivation 
of MSCs from hESCs renders additional MSC-derivation surgery to 
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biopsies are made from patients to isolate MSCs and the resultant 
cells are propagated in vitro, a marked decrease in the replicative 
competence and differentiation potential of the MSCs is consistently 
noticed over time and passage number 43. Capitalising on the lack 
of cellular senescence associated with hESCs should allow for the 
generation of larger numbers of MSCs and subsequently larger 
volumes of tissue for use in regenerative medicine applications. 
There has been no direct comparison reported to date between 
hESC-derived MSCs and those derived from somatic sources. Such 
a report, encompassing a discussion of senescence, differentiation 
capabilities and the in vivo stability of the cells would begin to 
determine whether hESCs are indeed a superior source of MSCs 
for therapeutic purposes. If hESCs are deemed to be superior as a 
supply of MSCs, and universal guidelines for their clinical use are 
consequently established, preparations can be made to generate an 
unlimited, universal donor line of MSCs from hESCs. Patients with 
osteochondral or indeed musculoskeletal defects may theoretically 
be treated with a line of MSCs of human origins to GMP standards. 
In addition to the use of hESC-derived MSCs for purposes directly 
applicable to tissue engineering, a limitless supply of MSCs may 
facilitate our understanding of both skeletal system development 
and of MSC biology, which is still not fully elucidated, . Identifying a 
novel method of isolating homogenous populations of MSCs through 
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isolation of a relatively homogeneous cellular population, however 
the identity of the antigenic component of STRO-1 remains elusive, 
and antibodies raised against other putative surface antigens of 
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subscription to the assumption that differentiation of hESCs in vitro 
recapitulates embryogenesis in utero could provides a platform from 
which to theorise and study early events in human skeletogenesis. 
Finally, MSCs derived from somatic sources have recently been 
demonstrated to possess immuno-modulatory traits 45-49. Coupling 
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their derivation from a unlimited source population and reported 
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scope of future MSC work to encompass their involvement in many 
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immune diseases. The authors have come to believe that although 
obtaining a new source of MSCs and their associated differentiated 
progeny will still augment our range our tools in the regenerative 
NFEJDJOF¾FME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remain to be appreciated. 
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